Invent Medic signs agreement with consultancy to facilitate start-up of US subsidiary for market and sales-related activities
Invent Medic announces that the company has signed an agreement with MLVB Inc, a consultancy focused on assisting Swedish medical technology companies during expansion to the US market. This cooperation is expected to facilitate Invent Medic’s ongoing process to establish its business in the US, including the start-up of a subsidiary for regional market and sales-related activities.
The start-up of a subsidiary constitutes an important part of Invent Medic’s expansion to the United States as this is required to handle the company’s market and sales activities in the region in an optimal way. It will also facilitate the presentation of company activities and results to shareholders and other stakeholders.
“It is exciting to have a collaboration partner in place for the start-up of our subsidiary in the United States. I look forward to collaborating with Marcie Coyne, who is in charge of MLVB Inc, within this and related areas,” says Invent Medic’s CEO Karin Bryder.
Invent Medic recently applied for market registration in the United States of its product Efemia bladder support. More than 20 million women in the United States are estimated to use some form of protection against stress incontinence and thus constitute potential users of Efemia bladder support.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.
SenzaGen får order på 0,6 MSEK från ny europeisk kund inom kemikalieindustrin
SenzaGen har erhållit en order värd 0,6 MSEK från en ny global kund inom kemikalieindustrin. Ordern omfattar SenzaGens tester för att bedöma om kemiska produkter kan orsaka allergiska reaktioner på hud (GARD®skin) respektive i luftvägarna (GARD®air). Testerna kommer att utföras i SenzaGens GLP-certi...
SenzaGen secures SEK 0.6 m order from a new European customer in the chemical industry
SenzaGen has received an order with a value of approximately SEK 0.6 million from a new global customer in the chemical industry. The order includes SenzaGen's tests to assess whether chemical substances in products can cause allergic reactions to skin (GARD™skin) or in the respiratory tract (GA...
Monivent meddelar sista dag för handel med teckningsoptioner av serie TO 1
Den 2 mars 2021, är den sista dagen för handel med teckningsoptioner av serie TO 1 som emitterades i samband med Monivent AB:s (“Monivent” eller “Bolaget”) emission av units i februari 2020. Nyttjandeperioden löper till och med den 4 mars 2021. Varje teckningsoption av serie TO 1 ger innehavaren rät...